期刊
DRUG DISCOVERY TODAY
卷 26, 期 11, 页码 2575-2592出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.06.008
关键词
Adjuvants; Administration routes; Delivery systems; Immunogenicity; Plasmid DNA vaccines
资金
- FEDER funds through the POCI-COMPETE 2020 - Operational Programme Competitiveness and Internationalization in Axis I-Strengthening research, technological development and innovation program [POCI-01-0145-FEDER-007491]
- National Funds from the FCT (Foundation for Science and Technology) [UID/Multi/00709/2019]
- FCT [2020.10201.BD]
- Fundação para a Ciência e a Tecnologia [UID/Multi/00709/2019, 2020.10201.BD] Funding Source: FCT
DNA vaccines are innovative approaches that show great potential in overcoming the limitations of traditional vaccines. While plasmid DNA vaccines have numerous advantages, there are still challenges in improving their immunogenicity.
DNA vaccines have emerged as innovative approaches that have great potential to overcome the limitations of current conventional vaccines. Plasmid DNA vaccines are often safer than other vaccines because they carry only antigen genetic information, are more stable and easier to produce, and can stimulate both humoral and cellular immune responses. Although the results of ongoing clinical trials are very promising, some limitations compromise the immunogenicity of these vaccines. Thus, this review describes different strategies that can be explored to improve the immunogenicity of plasmid DNA vaccines, including the optimization of the plasmid vector backbone, the use of different methods for vaccine delivery, the use of alternative administration routes and the inclusion of adjuvants. In combination, these improvements could lead to the successful clinical use of plasmid DNA vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据